S&P 500 Futures Drop In Premarket Trading; Intra-Cellular Therapies, Avantor Lag

Dow JonesDec 17 20:30

Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...

BenzingaDec 11 21:08

Intra-Cellular Therapies(ITCI.US) Officer Sells US$8.72 Million in Common Stock

$Intra-Cellular Therapies(ITCI.US)$ Officer Mates Sharon sold 102.7K shares of common stock on Dec 4, 5, 2024 at an average price of $84.9343 for a total value of $8.72 million.Source: Announcement

Futu NewsDec 7 07:06

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Simply Wall StDec 4 02:53

Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder

MT NewswiresDec 3 23:59

Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

BreakingsDec 3 20:30